Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital

RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps an Outperform rating on the shares. Following the recent Wainua approval, the firm’s survey of 43 neurologists to gauge expectations on the launch indicated that while the frequent dosing vs. Alnylam (ALNY) is viewed as a disadvantage, that was more than offset by self-injected at-home administration, which is particularly appealing to younger patients living far from academic institutions, the analyst tells investors in a research note.